JP2020533289A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533289A5
JP2020533289A5 JP2020513340A JP2020513340A JP2020533289A5 JP 2020533289 A5 JP2020533289 A5 JP 2020533289A5 JP 2020513340 A JP2020513340 A JP 2020513340A JP 2020513340 A JP2020513340 A JP 2020513340A JP 2020533289 A5 JP2020533289 A5 JP 2020533289A5
Authority
JP
Japan
Prior art keywords
cells
cell
combination
subject
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020513340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049812 external-priority patent/WO2019051135A1/en
Publication of JP2020533289A publication Critical patent/JP2020533289A/ja
Publication of JP2020533289A5 publication Critical patent/JP2020533289A5/ja
Priority to JP2022198485A priority Critical patent/JP2023030005A/ja
Pending legal-status Critical Current

Links

JP2020513340A 2017-09-06 2018-09-06 養子細胞治療を改善するための方法 Pending JP2020533289A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022198485A JP2023030005A (ja) 2017-09-06 2022-12-13 養子細胞治療を改善するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555034P 2017-09-06 2017-09-06
US62/555,034 2017-09-06
PCT/US2018/049812 WO2019051135A1 (en) 2017-09-06 2018-09-06 METHODS FOR IMPROVING ADOPTIVE CELL THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022198485A Division JP2023030005A (ja) 2017-09-06 2022-12-13 養子細胞治療を改善するための方法

Publications (2)

Publication Number Publication Date
JP2020533289A JP2020533289A (ja) 2020-11-19
JP2020533289A5 true JP2020533289A5 (enExample) 2021-10-21

Family

ID=63714040

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513340A Pending JP2020533289A (ja) 2017-09-06 2018-09-06 養子細胞治療を改善するための方法
JP2022198485A Pending JP2023030005A (ja) 2017-09-06 2022-12-13 養子細胞治療を改善するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022198485A Pending JP2023030005A (ja) 2017-09-06 2022-12-13 養子細胞治療を改善するための方法

Country Status (5)

Country Link
US (1) US12350312B2 (enExample)
EP (1) EP3678690A1 (enExample)
JP (2) JP2020533289A (enExample)
CN (1) CN111065410A (enExample)
WO (1) WO2019051135A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069241A1 (en) * 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
IL286971B1 (en) * 2019-04-05 2026-08-01 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with chimeric antigen receptor (CAR-T) cells
GB202006903D0 (en) * 2020-05-11 2020-06-24 Adaptimmune Ltd Modified iPSCs
EP4168451A2 (en) 2020-06-22 2023-04-26 NGM Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
RU2020122141A (ru) * 2020-07-03 2022-01-04 Максим Петрович Никитин Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови
CN116802278A (zh) * 2020-09-18 2023-09-22 成都美杰赛尔生物科技有限公司 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA114536A (en) 1908-09-18 1908-10-13 Adolphe Chalas Nickel recovering process
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2008042814A2 (en) 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
KR101319499B1 (ko) 2008-02-22 2013-10-17 엘지디스플레이 주식회사 화학적 자기조립 방법을 이용한 나노선 혹은탄소나노튜브의 적층 및 패턴형성 방법과, 이를 적용한액정표시장치의 제조방법
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
US9316646B2 (en) 2009-04-23 2016-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
DK3246042T3 (da) 2009-11-02 2019-10-14 Univ Emory Lægemiddelresistent immunterapi til behandling af cancer
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
AU2013361275B2 (en) 2012-12-19 2016-11-24 Amplimmune, Inc. Anti-human B7-H4 antibodies and their uses
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
US10752684B2 (en) * 2014-07-29 2020-08-25 Cellectis ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapy
TW201625689A (zh) 2014-09-12 2016-07-16 建南德克公司 抗－ｂ７－ｈ４抗體及免疫結合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
WO2016172583A1 (en) * 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
WO2017019767A1 (en) * 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
PT3393504T (pt) * 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
WO2017214207A2 (en) 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
EP3484455A2 (en) * 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US20210145882A1 (en) 2018-04-13 2021-05-20 Fred Hutchinson Cancer Research Center Methods for adoptive cell therapy targeting ror1

Similar Documents

Publication Publication Date Title
US11458191B2 (en) Binding proteins specific for RAS neoantigens and uses thereof
JP7037577B2 (ja) 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用
US20210069241A1 (en) Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US20240165232A1 (en) Chimeric receptor proteins and uses thereof
US20210145882A1 (en) Methods for adoptive cell therapy targeting ror1
US12350312B2 (en) Methods for improving adoptive cell therapy
JP7407701B2 (ja) ｓｔｒｅｐタグ特異的キメラ受容体およびその使用
US20210340201A1 (en) Immunotherapy targeting kras or her2 antigens
JP2021534752A5 (enExample)
US20220267403A1 (en) Binding proteins specific for 5t4 and uses thereof
JP2020533962A (ja) Ｂｒａｆ特異的ｔｃｒおよびその使用
JP2022525099A (ja) 高アビディティｗｔ１ｔ細胞受容体とその使用
JP7737978B2 (ja) Ｗｔ－１に特異的なｔ細胞免疫療法
US20220009992A1 (en) T cell receptors specific for mesothelin and their use in immunotherapy
US20250177531A1 (en) Binding proteins specific for ras neoantigens and uses thereof
US20220401537A1 (en) Chimeric receptor proteins and uses thereof
WO2022076353A1 (en) Compositions and methods for treating mage-a1-expressing disease